Does methylene blue slow ageing or sharpen the mind?
The claim
Low-dose methylene blue, taken orally, improves mitochondrial energy production in brain cells, which proponents say sharpens memory and focus in healthy people and slows biological ageing.
The case for
“In short, MB has the potential to do much of the heavy lifting to help stave off many of the ravages of aging, way beyond what its original discoverers could have even imagined back in the day.”
Frank Lipman, author, drfranklipman.com · 2024-04-22 · source
“By enhancing cognitive agility and clearing brain fog, it's the secret weapon that keeps you sharp, energized, and ready to tackle any task.”
Troscriptions, maker of Blue Cannatine, a methylene blue troche · 2026 · source
The case against
“Small studies in healthy adults have explored memory and brain activity, but lasting cognitive benefits remain unproven”
Raphael E. Cuomo, professor of medicine, University of California San Diego · 2026-10-30 · source
“Overall, while scientists have found hints of some fascinating properties of methylene blue, much larger, longer trials are needed to know if it truly works, what the right dose is and how safe it is over time.”
Lorne J. Hofseth, Professor and Associate Dean for Research, College of Pharmacy, University of South Carolina · 2025-06-03 · source
Quotes are short extracts, in the speakers' own words, about the claim or the evidence; each links to where it was said. Inclusion is not endorsement.
What the sources say
Evidence for this claim 3/10 · early human evidence
Methylene blue is a century-old dye whose only FDA-approved use is treating acquired methaemoglobinaemia, a blood disorder; its label carries a boxed warning for serotonin syndrome when it is combined with serotonergic drugs or opioids. The one randomised trial in healthy adults gave 26 people a single low oral dose and found more brain activity on fMRI during attention and short-term memory tasks, and a 7 percent rise in correct memory responses an hour later. No trial has tested repeated doses in healthy people or measured any ageing outcome. The largest human trials used LMTM, a related compound, in Alzheimer's disease, and a 15-month trial of 891 patients found no benefit on its primary outcomes. In a National Institute on Aging mouse study, methylene blue did not extend median lifespan in either sex.
Scores cognition and ageing in healthy people; not methaemoglobinaemia, where methylene blue is an approved treatment.
The record
- Trial2016 · In 2016 a randomised, double-blind, placebo-controlled trial in 26 healthy adults (aged 22-62) found that a single low oral dose of methylene blue increased fMRI activity during attention and short-term memory tasks and was associated with a 7% increase in correct memory-retrieval responses one hour after dosing; it did not test repeated use or ageing outcomes. source
- Trial2016-12 · In 2016 a 15-month phase 3 trial of 891 people with mild to moderate Alzheimer's disease found no benefit on either co-primary cognitive or daily-living outcome from LMTM, a stabilised reduced form of methylthioninium (the active moiety of methylene blue). source
- Trial2018 · In 2018 a revised, non-randomised cohort analysis of an 800-patient phase 3 LMTM trial in mild Alzheimer's reported better outcomes in a monotherapy subgroup, with the authors stating that a further suitably randomised trial is required to test the hypothesis. source
- Trial2014 · In a 2014 National Institute on Aging Interventions Testing Program study in genetically heterogeneous mice, methylene blue did not alter median lifespan in either sex and produced a small (6%) increase in female maximum lifespan; there are no human lifespan or ageing-rate data. source
- Regulator2024 · The FDA-approved label for ProvayBlue (methylene blue injection, revised 2024) lists a single indication, acquired methaemoglobinaemia, and carries a boxed warning that it may cause serious or fatal serotonin syndrome with serotonergic drugs and opioids; it is contraindicated in G6PD deficiency. source
Sources: drfranklipman.com, troscriptions.com, politifact.com, theconversation.com, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, accessdata.fda.gov, pubmed.ncbi.nlm.nih.gov.
Compiled by the Alivewire editors from the sources above, ; evidence last checked . This page describes the published evidence on a claim; it makes no judgement about the people who make it. We rely on sources we consider reputable but do not independently verify the facts they report. Not medical advice.
If you are quoted here and believe we have misstated your position, or if the evidence has moved, please tell us; an editor checks every report and corrects the page when it holds. How claims pages work.
Explainer and coverage: Methylene blue